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ABSTRACT 
Objective: The purpose of this study was to formulate Ritonavir floating matrix tablets by melt granulation technique in order to prolong its gastric 
residence time thereby increasing its bioavailability.  
Methods: The Ritonavir tablets were prepared by melt granulation technique, using carriers such as Gelucire 43/01, Gelucire 50/02 and Geleol 
pellets alone or in combinations. Ethyl cellulose was used as drug release rate retarding agent and sodium bicarbonate was used as gas generating 
agent. The prepared granules were subjected to pre and post compressional parameters. The formulations were optimized on the basis of matrix 
integrity, duration of floating, swelling behavior and In vitro drug release.  
Results: The drug-excipients compatibility studies were performed by FT-IR and the study revealed that there is no drug excipients interaction. A 
combined matrix system containing Gelucire 43/01: Gelucire 50/02 with 1:1 concentration along with HPMC K 15 M shows good drug release 
pattern with less floating lag time and increased floating duration.  
Conclusion: The in vitro drug release pattern of Ritonavir floating tablets was fitted to different kinetic models which showed the highest 
regression for Zero order kinetics with Higuchi mechanism. 
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INTRODUCTION 
Gastro retentive drug delivery systems help prolongs the overall 
gastrointestinal transit time and improves the oral bioavailability of the 
drugs that are having site specific absorption from the stomach, i.e., the 
upper part of small intestine. Therefore, different approaches have been 
proposed to retain the dosage form in the stomach including bioadhesive 
system, swelling and expanding systems, floating systems and delayed 
gastric emptying devices [1-3]. The principle of buoyant preparation 
offers a simple and practical approach to achieve increased gastric 
residence time of the dosage form and sustained drug release [4]. 
Ritonavir is human immunodeficiency virus (HIV) protease inhibitor 
used at the antiretroviral agent, and its biological half-life is 3-5 h [5]. 
Ritonavir requires multiple daily doses in order to maintain adequate 
plasma concentrations. Therefore, it would be a suitable model 
candidate for gastro retentive formulation.  
The gastro-retentive drug delivery systems can be retained in the 
stomach and assist in imposing the oral sustained delivery of the drug 
that has absorption window in a particular region of gastric tract [6]. 
These systems help in the continuous release of the drug before it 
reaches the absorption window thus ensuring optimal bioavailability.  
Gelucire 43/01 and 50/02 and Geleol were used as carrier forming 
materials and hydroxypropyl methylcellulose (HPMC) and EC are used 
as controlled release polymers [7, 8]. Sodium bicarbonate is used as 
gas generating agent. Gelucires are a family of vehicles derived from 
mixtures of mono-, di-, and triglycerides with polyethylene glycol 
(PEG) esters of fatty acids. Gelucire are available with a range of 
properties depending on their hydrophilic lipophilic balance (HLB 1-
18) and melting point (33OC-65OC) range [9-11]. Gelucire containing 
only PEG esters (Gelucire 55/18) are generally used in the preparation 
of fast-release formulations while Gelucire containing only glycerides 
or a mixture of glycerides and PEG esters (Gelucire 54/02, 50/13, 
43/01) are used in the preparation of sustained-release formulations. 
The main objective of the present study is to formulate gastro 
retentive Ritonavir drug delivery systems by melt granulation 
method using carriers such as Gelucire 43/01, Gelucire 50/02 and 
Geleol pellets alone or in combinations. 
MATERIALS AND METHODS 
Materials 
Gelucire (43/01 and 50/02) and Geleol were obtained from Gattefosse 
(St Priest, Cedex, France) as gift samples. HPMC 15 K, ethyl cellulose, 
and other excipients were purchased from S. D fine chemicals. 
Table 1: Formulation of floating ritonavir tablets 
Ingredients (mg) F1 F2 F3 F4 F5 F6 F7 F8 F9 F10 F11 F12 
Ritonavir 100 100 100 100 100 100 100 100 100 100 100 100 
Gelucire 43/01 50 --- --- 75 --- --- 100 --- --- 50 --- 50 
Gelucire 50/02 --- 50 --- --- 75 --- --- 100 --- 50 50 --- 
Geleol pellets --- --- 50 --- --- 75 --- --- 100 --- 50 50 
HPMC K15 80 80 80 80 80 80 80 80 80 80 80 80 
Ethyl cellulose 30 30 30 30 30 30 30 30 30 30 30 30 
Sodium bicarbonate 30 30 30 30 30 30 30 30 30 30 30 30 
MCC 64 64 64 39 39 39 14 14 14 39 39 39 
Magnesium stearate 3 3 3 3 3 3 3 3 3 3 3 3 
Talc 4 4 4 4 4 4 4 4 4 4 4 4 
Total weight (mg) 360 360 360 360 360 360 360 360 360 360 360 360 
HPMC K15-Hydroxy propyl methyl cellulose, MCC-Microcrystalline cellulose 
International Journal of Applied Pharmaceutics 
ISSN- 0975-7058                               Vol 8, Issue 3, 2016 
Velivela et al. 
Int J App Pharm, Vol 8, Issue 3, 2016, 12-15 
13 
Preparation of ritonavir floating tablets [12-14] 
Gelucire (43/01and 50/02) and Geleol were melted in a china dish 
at their melting points, and a required quantity of Ritonavir was 
added to the molten mass. Previously prepared mixture containing 
HPMC K15, sodium bicarbonate, ethyl cellulose, microcrystalline 
cellulose were added to drug-Gelucire (43/01 and 50/02) and Geleol 
mixture. Here, Sodium bicarbonate was added as gas generating 
agent. It was mixed to prepare uniform mass and sieved through 44 
mesh. Lastly, talc and magnesium stearate were added. The 
lubricated blends were compressed using rotary tablet press. 
Evaluation methods for ritonavir floating tablets 
1. In vitro buoyancy studies 
The prepared Ritonavir floating tablet was placed in 900 ml of 0.1 N 
HCL in a vessel maintained at 37±0.5OC and stirred at 50 rpm in a US 
Pharmacopeia (USP) type II dissolution test apparatus, Mumbai, 
India). The percentage of floating granules up to 12 h was determined, 
and the floating times were measured by visual observation. 
2. In vitro drug release studies [15] 
The release of drug from granules containing the different drug to 
lipid proportions with and without the release rate modifier was 
investigated. Studies were performed in triplicate using a (USP) type 
II dissolution test apparatus with an agitation speed of 50 rpm in 0.1 
N HCL maintained at 37±0.5 OC. At appropriate time intervals, the 
samples were withdrawn and assayed spectrophotometrically at 
256 nm after filtration through Whatman filter paper and with 
suitable dilutions. The methodology for in vitro dissolution was kept 
the same for all the batches prepared. 
3. Selection of lipid carrier 
The preliminary screening was performed to select the best lipid 
carrier among Gelucire 43/01, and Gelucire 50/02 and Geleol. 
Formulations were prepared using various drug-to-carrier ratios 
(1:0.5, 1:0.75 and 1:1). The selection of polymers was based on tests 
for floating behavior and in vitro drug release studies. 
4. Kinetic modeling of drug release [16, 17] 
The dissolution profile of all the batches was fitted to zero-order, 
first-order, Higuchi, Korsmeyer and Peppas to ascertain the kinetic 
modeling of drug release. 
RESULTS AND DISCUSSION 
Ritonavir floating tablets were developed to increase the gastric 
residence time of the drug so that they can be retained in the 
stomach for a longer time and help in the controlled release of the 
drug to a minimum of 12h. 
Preformulation studies 
Compatibility among drug and optimized polymer i.e. Gelucire 
43/021 and Gelucire 50/02 were assessed by performing IR 
Spectroscopic studies. There was no interaction between the drug 
and polymers were observed as, the principle peaks of the drug 
were found unaltered in the IR Spectra. Granules of various 
formulations containing drug and meltable binder were evaluated 
for angle of repose, bulk density, tapped density and Carr’s index. All 
formulations were found to be in the acceptable range. 
Post compressional parameters 
Each formulation was evaluated for parameters such as weight 
variation, drug content, hardness, friability, floating behavior and in 
vitro drug release. The weights and friability of all formulations were 
within the range according to IP. Weight lose in the friability test 
was less than 0.6% in all the cases. The hardness was in the range of 
2.1±0.2 to 3.0±0.3 Kg/cm2, which was due to the use of waxy 
polymers; it also indicated that the increase in carrier content 
increases the crushing strength of tablets.  
In vitro dissolution studies of prepared tablets 
All Formulations were subjected to in vitro dissolution study. All 
Tablets retained their integrity throughout the study and released 
the drug in controlled manner as shown in the fig. 1. 
Three batches of formulations (F1, F2, and F3) as shown in table 1 were 
prepared using 14% of polymers Gelucire 43/01, 50/02 and Geleol 
respectively while the same optimum amount of sodium bicarbonate 
(8%) used. From the evaluation results, it was observed that the three 
formulations failed to release the drug up to 12 h, indicating less 
concentration (14%) of lipoidal polymer. Whereas F6 contained 20% 
concentration of geleol which didn’t satisfactory sustained drug release. 
Less floating lag time and more floating duration were obtained in the 
case of the formulations containing different concentrations of Gelucire 
43/01 (F4, F7, F10 and F12). The Gelucire 43/01 in combination with 
Gelucire 50/02 and Gelucire 43/01 in combination with Geleol were 
present in the formulation batches F10 & F12 respectively. This 
implicates that with an increase in the concentration of lipoidal polymer 
more floating duration was achieved. The formulations containing 
Gelucire 50/02 either individually has shown to extend the drug release 
with an increase in its concentration. In case of F10 formulation, better 
results containing Gelucire 50/02 in a combination of Gelucire 43/01 
was observed.  
F3, F6, F9 contained Geleol individually in increasing concentration; it 
was observed that the drug release was also sustained with 
concentrations. In F11 and F12, the satisfactory drug release, floating 
lag time and floating duration were obtained, where geleol was 
present in combination with Gelucire 50/02 and 43/01 respectively. 
F11 and F12 formulations were less in comparison with F10 
formulation in terms of floating lag time and floating duration. 
Among all formulations, tablets of batch F10 released 98% of a drug 
within 12 h, which was according to the need for the therapy, which 
contains 28 % of Gelucire 43/01 and Gelucire 50/02 in combination 
which was the highest amount of polymer. Hence, it was decided to 
keep total polymer concentration at 28% for acceptable formulation in 
further study. 
Drug content and floating studies 
The drug content was in the range of 90.66±1.03 to 98.83±0.56 % 
which reflects good uniformity in drug content among different 
formulations. The time taken for the tablets to rise to the surface and 
float is the floating lag time. The gas generated is trapped and 
protected within the gel, formed by hydration of the polymer, thus 
decreasing the density of the tablet. As the density of the tablet falls 
below 1, the tablet became buoyant. The floating lag time ranged 
between 55 sec to 22 min. 
 
Table 2: In vitro drug release of prepared floating tablets of ritonavir 
Time (H) Cumulative % of drug release (n=3) mean±SD 
F1 F2 F3 F4 F5 F6 
0 0 0 0 0 0 0 
1 28.7±0.23 39.6±0.45 21.23±0.23 16.82±0.35 18.65±0.59 22.45±0.59 
2 56.8±1.35 62.3±0.01 52.03±0.542 49.83±0.47 32.19±1.23 40.60±0.51 
4 86.2±0.21 77.7±1.37 89.62±0.29 64.2±1.21 52.21±1.56 69.54±0.84 
6 91.1±0.32 96.2±0.42 98.63±0.36 76.8±0.26 70.22±0.28 80.28±0.54 
8 --- --- --- 89.62±0.774 83.3±0.87 99.32±0.60 
10 --- --- --- 97.3±1.35 92.28±0.49 --- 
12 --- --- --- --- --- --- 
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The hydrophobic meltable material in all the formulations imparted 
sufficient integrity to the tablets. HPMC K15 (hydrophilic) was 
selected as a matrixing agent considering its widespread 
applicability and excellent gelling activity in sustained release 
formulations. Sodium bicarbonate generates CO2 gas in a presence of 
hydrochloric acid present in the dissolution medium. Generated gas 
is trapped and protected within a gel formed by hydration of HPMC 
K15; thereby decreasing the density of the tablet becomes buoyant.
 
Table 3: In vitro drug release of prepared F7-F12 floating tablets of ritonavir 
Time (H) Cumulative % of drug release (n=3) mean±SD  
 F7 F8 F9 F10 F11 F12 
0 0 0 0 0 0 0 
1 19.82±1.88 14.26±1.45 6.83±0.54 32.19±0.56 23.64±0.88 14.26±0.98 
2 22.45±0.89 20.42±0.45 20.33±0.22 41.1±0.23 38.13±0.61 21.62±0.87 
4 27.56±0.62 28.51±1.89 23.64±1.03 58.92±0.70 47.05±1.20 54.53±1.23 
6 40.75±0.35 33.74±1.32 26.97±1.99 65.74±1.06 57.14±1.35 61.9±1.56 
8 56.9±1.64 54.23±0.51 32.53±1.23 78.88±1.22 67.84±1.65 64.03±1.99 
10 64.86±1.05 65.71±0.54 49.06±1.45 85.66±0.87 70.09±1.24 78.89±1.54 
12 70.1±0.94 69.7±1.03 57.06±1.03 98.67±0.47 82.26±1.23 81.23±1.89 
 
Table 4: Drug content and floating studies of F1-F12 formulations 
Formulation code 
 





Floating lag time Floating duration (hrs) 
F1 94.2±0.23 70.03 20 min 4 
F2 95.06±0.54 75.70 22 min 5 
F3 96.78±0.21 69.54 20 min 3 
F4 96.89±0.89 80.18 55 Sec 12 
F5 92.03±0.23 77.89 5 min 10 
F6 95.58±0.41 76.58 40 Sec 8 
F7 91.78±0.65 79.08 90 Sec 12 
F8 95.62±0.28 74.56 2.2 min 10 
F9 90.66±1.03 68.87 1.2 min 11 
F10 92.16±0.54 69.21 45 Sec 12 
F11 98.83±0.56 80.23 1.5 min 10 
F12 94.01±0.66 78.68 2 min 10 
 
Release kinetics 
The optimized formulation F10 was found to have following typical 
zero order kinetics, which clearly indicated by their relatively higher 
“r” values compared to the first order regression coefficient values 
and follows Higuchi diffusion as release model and korsmeyer-
peppas model and entire exponent ‘n’ values were found to be in 
between 0.5-1, indicating that all the formulations were following 
non-fickian mode of drug release. 
 
Table 5: Pharmacokinetic modeling of ritonavir floating tablets 
Formulation code Relative regression coefficient values (r) n 




F1 0.887 0.976 0.901 0.882 0.942 0.656 
F2 0.877 0.944 0.807 0.87 0.979 0.479 
F3 0.931 0.966 0.781 0.929 0.947 0.87 
F4 0.895 0.951 0.818 0.89 0.899 0.698 
F5 0.963 0.98 0.851 0.959 0.996 0.702 
F6 0.954 0.816 0.635 0.949 0.987 0.706 
F7 0.961 0.976 0.89 0.954 0.918 0.55 
F8 0.972 0.965 0.859 0.967 0.958 0.654 
F9 0.949 0.937 0.843 0.944 0.914 0.737 
F10 0.907 0.827 0.688 0.899 0.992 0.444 
F11 0.898 0.969 0.931 0.889 0.984 0.569 
F12 0.904 0.969 0.922 0.9 0.952 0.732 
 
 
Fig. 1: In vitro dissolution plots of F1 to F6 
 
Fig. 2: In vitro dissolution plots of F7 to F12: 
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CONCLUSION 
In present study controlled release floating matrix tablet of Ritonavir 
was successfully prepared utilizing Melt Granulation technique with 
appropriate hardness and thickness. The in vitro drug release studies of 
prepared Ritonavir tablets were studied separately according to their 
proportions (1:0.5, 1:0.75, 1:1 and their combinations) using 0.1N HCl as 
dissolution media. Floating was successfully achieved at the taken 
concentration of Sodium Bicarbonate and HPMC K15. In terms of lipidic 
polymers a combination of Gelucire 43/01 and Gelucire 50/02 in a ratio 
of 1:1 to the drug (F10) was appropriate, which showed least floating lag 
time and highest floating duration. Among all the formulations, 
formulation F10 showed promising results releasing 98.67% of the drug 
in 12Hrs with a floating lag time of 55 sec and total floating time of 12 h. 
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